N-[4-methyl-2-(4-morpholinyl)-6-quinolinyl]cyclohexanecarboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-[4-methyl-2-(4-morpholinyl)-6-quinolinyl]cyclohexanecarboxamide
• 英文别名: N-(4-methyl-2-morpholin-4-ylquinolin-6-yl)cyclohexanecarboxamide
• 化学式: C₂₁H₂₇N₃O₂
• 分子量: 353.5
• InChiKey: BXVNPOBNVRBOOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• TARGETED PEPTIDE CONJUGATES
  申请人：Marker Gene Technologies, Inc.

  公开号：US20180207287A1

  公开（公告）日：2018-07-26

  The present invention relates to the preparation and use of therapeutic compounds for the treatment of diseases at specific subcellular target areas such as specific cellular organelles. In particular, the therapeutic compounds of the invention are specific for modifying enzyme activity within targeted organelles or structures of cells and tissues. Subcellular organelles and structures that may be specifically targeted by compounds of the present invention include lysosomes, autophagasomes, the endoplasmic reticulum, the Golgi complex, peroxisomes, the nucleus, membranes and the mitochondria.

  本发明涉及制备和使用治疗化合物，用于治疗特定亚细胞靶区域的疾病，如特定细胞器。具体来说，本发明的治疗化合物特异地用于修改靶向细胞和组织的细胞器或结构内的酶活性。本发明的化合物可以特异地靶向的亚细胞器和结构包括溶酶体、自噬体、内质网、高尔基体、过氧化物酶体、细胞核、细胞膜和线粒体。
• Targeted peptide conjugates
  申请人：Marker Gene Technologies, Inc.

  公开号：US10543282B2

  公开（公告）日：2020-01-28

  The present invention relates to the preparation and use of therapeutic compounds for the treatment of diseases at specific subcellular target areas such as specific cellular organelles. In particular, the therapeutic compounds of the invention are specific for modifying enzyme activity within targeted organelles or structures of cells and tissues. Subcellular organelles and structures that may be specifically targeted by compounds of the present invention include lysosomes, autophagasomes, the endoplasmic reticulum, the Golgi complex, peroxisomes, the nucleus, membranes and the mitochondria.

  本发明涉及用于治疗特定亚细胞靶区（如特定细胞器）疾病的治疗化合物的制备和使用。特别是，本发明的治疗性化合物对改变细胞和组织的目标细胞器或结构内的酶活性具有特异性。本发明化合物可特异性靶向的亚细胞器和结构包括溶酶体、自噬体、内质网、高尔基复合体、过氧物酶体、细胞核、细胞膜和线粒体。
• TREATMENT OF PROTEINOPATHIES
  申请人：The General Hospital Corporation

  公开号：EP2723384A1

  公开（公告）日：2014-04-30
• MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS
  申请人：ModernaTX, Inc.

  公开号：US20220184185A1

  公开（公告）日：2022-06-16

  This disclosure relates to treatment of lysosomal storage disorders, such as Fabry disease or Gaucher disease, with a combination treatment containing (i) an mRNA encoding a lysosomal enzyme deficient in the lysosomal storage disorder, and (ii) a compound that is a glucosylceramide synthase inhibitor or a pharmacological chaperone of the lysosomal enzyme. mRNAs for use in the invention, when administered in vivo, encode the enzyme that is deficient in the lysosomal storage disorder, functional fragments thereof (e.g., those comprising the catalytic domain), or fusion proteins containing the enzyme that is deficient in the lysosomal storage disorder. mRNA therapies can be used to increase and/or restore deficient levels of a lysosomal enzyme's expression and/or activity in subjects.
• US9845327B2
  申请人：——

  公开号：US9845327B2

  公开（公告）日：2017-12-19